Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Vodis Pharmaceuticals

CNSX:VP
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VP
CNSX
CA$3M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Vodis Pharmaceuticals Inc. operates as an application stage company for producing medical marijuana in Canada and the United States. The last earnings update was 95 days ago. More info.


Add to Portfolio Compare Print
  • Vodis Pharmaceuticals has significant price volatility in the past 3 months.
VP Share Price and Events
7 Day Returns
-33.3%
CNSX:VP
-13.8%
CA Pharmaceuticals
-6.2%
CA Market
1 Year Returns
-65.2%
CNSX:VP
-65.6%
CA Pharmaceuticals
-2%
CA Market
VP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vodis Pharmaceuticals (VP) -33.3% -20% -11.1% -65.2% -91.8% -
CA Pharmaceuticals -13.8% -22.6% -20.7% -65.6% 0.8% 283%
CA Market -6.2% -5% -2.8% -2% 0.6% 8.9%
1 Year Return vs Industry and Market
  • VP matched the Pharmaceuticals industry (-65.6%) over the past year.
  • VP underperformed the Market in Canada which returned -2% over the past year.
Price Volatility
VP
Industry
5yr Volatility vs Market

Value

 Is Vodis Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Vodis Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vodis Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vodis Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is CA$0.04.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vodis Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vodis Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:VP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CAD CA$-0.06
CNSX:VP Share Price ** CNSX (2020-02-28) in CAD CA$0.04
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 14.69x
Canada Market PE Ratio Median Figure of 509 Publicly-Listed Companies 14.76x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vodis Pharmaceuticals.

CNSX:VP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:VP Share Price ÷ EPS (both in CAD)

= 0.04 ÷ -0.06

-0.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vodis Pharmaceuticals is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Vodis Pharmaceuticals is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Vodis Pharmaceuticals's expected growth come at a high price?
Raw Data
CNSX:VP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 1.38x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vodis Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vodis Pharmaceuticals's assets?
Raw Data
CNSX:VP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CAD CA$-0.02
CNSX:VP Share Price * CNSX (2020-02-28) in CAD CA$0.04
Canada Pharmaceuticals Industry PB Ratio Median Figure of 154 Publicly-Listed Pharmaceuticals Companies 1.28x
Canada Market PB Ratio Median Figure of 2,345 Publicly-Listed Companies 1.31x
CNSX:VP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:VP Share Price ÷ Book Value per Share (both in CAD)

= 0.04 ÷ -0.02

-1.88x

* Primary Listing of Vodis Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vodis Pharmaceuticals has negative assets, we can't compare the value of its assets to the CA Pharmaceuticals industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Vodis Pharmaceuticals's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Pharmaceuticals industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Vodis Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Vodis Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vodis Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vodis Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
69.4%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vodis Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Vodis Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Vodis Pharmaceuticals's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Vodis Pharmaceuticals's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:VP Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 69.4%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 39.9%
Canada Market Earnings Growth Rate Market Cap Weighted Average 9.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 4.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:VP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:VP Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-09-30 -1 -4
2019-06-30 -1 -4
2019-03-31 -1 -4
2018-12-31 -2 -4
2018-09-30 -2 -3
2018-06-30 -2 -3
2018-03-31 -2 -4
2017-12-31 0 -1 -4
2017-09-30 0 -1 -8
2017-06-30 0 -1 -7
2017-03-31 0 0 -6
2016-12-31 0 -1 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Vodis Pharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Vodis Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:VP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Vodis Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VP Past Financials Data
Date (Data in CAD Millions) EPS *
2019-09-30 -0.06
2019-06-30 -0.07
2019-03-31 -0.09
2018-12-31 -0.09
2018-09-30 -0.07
2018-06-30 -0.09
2018-03-31 -0.12
2017-12-31 -0.14
2017-09-30 -0.29
2017-06-30 -0.29
2017-03-31 -0.27
2016-12-31 -0.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vodis Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Vodis Pharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Vodis Pharmaceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Vodis Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vodis Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vodis Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vodis Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vodis Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Vodis Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vodis Pharmaceuticals's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Vodis Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vodis Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VP Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 -3.64 1.54
2019-06-30 -3.77 1.62
2019-03-31 -4.21 1.99
2018-12-31 -3.69 1.91
2018-09-30 -2.64 1.92
2018-06-30 -3.15 2.42
2018-03-31 -3.74 2.96
2017-12-31 -0.03 -4.00 3.13
2017-09-30 -0.02 -7.93 4.44
2017-06-30 0.00 -7.16 3.79
2017-03-31 0.01 -6.19 2.92
2016-12-31 0.11 -6.14 2.81
2016-09-30 0.11 -1.82 1.29
2016-06-30 0.09 -2.70 2.18
2016-03-31 0.08 -2.48 2.05
2015-12-31 0.02 -3.11 2.29
2015-09-30 0.01 -3.07 2.32
2015-06-30 -2.42 1.71
2015-03-31 -2.42 1.72
2014-03-31 -0.01 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vodis Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Vodis Pharmaceuticals has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vodis Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Vodis Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vodis Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vodis Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vodis Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vodis Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Vodis Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Vodis Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Vodis Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vodis Pharmaceuticals Company Filings, last reported 4 months ago.

CNSX:VP Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -1.27 0.02
2019-06-30 -1.19 0.02
2019-03-31 -0.99 0.02 0.02
2018-12-31 1.17 0.02 0.01
2018-09-30 0.60 0.22 0.17
2018-06-30 0.66 0.22 0.01
2018-03-31 0.69 0.21 0.44
2017-12-31 1.10 0.20 0.24
2017-09-30 -0.27 0.20 0.03
2017-06-30 0.25 0.20 0.02
2017-03-31 0.89 0.20 0.33
2016-12-31 1.59 0.20 0.86
2016-09-30 -0.12 0.82 0.10
2016-06-30 0.12 0.00 0.06
2016-03-31 0.38 0.06 0.00
2015-12-31 1.23 0.45 0.28
2015-09-30 0.56 0.44 0.08
2015-06-30 0.91 0.00 0.01
2015-03-31 0.27 0.00 0.43
2014-03-31 -0.01 0.00 0.00
  • Vodis Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Vodis Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vodis Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Vodis Pharmaceuticals has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Vodis Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vodis Pharmaceuticals has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vodis Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vodis Pharmaceuticals dividends.
If you bought CA$2,000 of Vodis Pharmaceuticals shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vodis Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vodis Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:VP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.7%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vodis Pharmaceuticals has not reported any payouts.
  • Unable to verify if Vodis Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vodis Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vodis Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vodis Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vodis Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vodis Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vodis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Lotz
AGE 55
TENURE AS CEO 0.9 years
CEO Bio

Mr. Mark Lotz, BBA, CA, CPA, serves as Interim Chief Executive Officer of Ascent Industries Corp. since January 10, 2020. Mr. Lotz has been Interim Chief Financial Officer and Director of of Ascent Industries Corp. since April 26, 2019. He had served as an Independent Director of Voleo Trading Systems Inc. since July 7, 2016 and serves as its Director. He serves as Chief Financial Officer & Director at Fiorentina Minerals Inc. since November 24, 2017 and its Corporate Secretary. Mr. Lotz, BBA, CA, CPA, serves as the Chief Financial Officer at Specialty Liquid Transportation Corp. (formerly Blue Bay Capital Inc.) since January 2019. Mr. Lotz served as the Interim Chief Executive Officer at Logan Resources Ltd. since April 19, 2019. He is the Chief Financial Officer of Candente Copper Corporation since October 1, 2018. He has been Consultant at Golden Lake Exploration Inc. since July 26, 2019. He served as Chief Financial Officer and Company Secretary at Golden Lake Exploration Inc. from May 17, 2018 to July 26, 2019 and served as its Director from June 26, 2018 to July 26, 2019. He serves as Consultant at Crest Resources Inc. since April 05, 2019. Mr. Lotz served as Chief Financial Officer and Director at Crest Resources Inc. until April 05, 2019. He has been Chief Executive Officer and Chief Financial Officer of World Mahjong Limited since February 28, 2017 and serves as its President. He has experience in senior finance roles in software, manufacturing, mining and the securities industries. Mr. Lotz served as an Advisor of Commander Resources Ltd. since June 8, 2016 until August 2018. He served as the Chief Financial Officer and Director of New Point Exploration Corp. from March 10, 2017 to March 1, 2018. He has experience primarily in the minerals industry and related securities businesses. He was the Chief Financial Officer and Corporate Secretary at Volatus Capital Corp. from November 6, 2018 until October 2019. He served as the Chief Financial Officer of Horizon Health International Corp. since August 3, 2006. He served as the Chief Financial Officer of Ferro Iron Ore corporation from April 1, 2012 to February 2013. He served as a Financial Consultant at Desert Mountain Energy Corp. (formerly, African Queen Mines Ltd.) from April 2012 to August 2012. He served as the Chief Financial Officer of African Queen Mines Ltd. from August 26, 2011 to April 16, 2012. Mr. Lotz served as the Chief Financial Officer of Sacre-Coeur Minerals, Ltd. from August 26, 2011 to August 7, 2012. He served as Chief Executive Officer of World Mahjong Limited since February 28, 2017. He served as the Chief Financial Officer at Horizons Holdings International, Corp. since August 3, 2006 and Fura Emeralds Inc. (now Fura Gems Inc.) from April 1, 2012 to February 5, 2013. He served as the Chief Financial Officer of Wolf Resource Development Corp. from April 01, 2012 to February 05, 2013. From 1999 to 2001, he served as the Chief Financial Officer of Destiny Media Technologies Inc. He also served as a Manager Customer Service Royal Bank of Canada from 1998 to 1990. He served as the Chief Financial Officer of TrackX Holdings Inc. He served as the Chief Financial Officer Prophecy Development Corp. from May 10, 2010 to September 30, 2010 and also served as its Executive Officer. He served as the Chief Executive Officer, President and Chief Financial Officer of Gateway Securities Inc. from February 2007 to May 2008. He served as the Chief Financial Officer of Golden Capital Securities Ltd. from January 2001 to February 2007. He has also served as a Senior Executive Officer for two Vancouver based securities firms and a financial compliance officer for the Vancouver Stock Exchange. He served as a Member of the Vancouver Stock Exchange Examiner and was responsible for reviewing financial & sales compliance of Vancouver based brokerage firms from 1995 to 1999. Prior to that, he served as a Financial Compliance Officer at the Vancouver Stock Exchange, following four years as a Senior Auditor with Coopers and Lybrand, focusing on the mining and tax sectors. He has been Director of Logan Resources Ltd. since July 8, 2016. He served as Independent Director at Canada Jetlines Ltd. until February 5, 2018. He served as Independent Director at Golden Raven Resources Ltd. since October 20, 2016. He served as an Independent Director of Jet Metal Corp. since April 1, 2014. He served as Independent Director of Commander Resources Ltd. from November 14, 2012 to June 8, 2016. He served as a Director of Archer Petroleum Corp from May 14, 2012 to February 13, 2013. He served as a Director of Sacre-Coeur Minerals Ltd. from August 26, 2011 to August 2012. He served as a Director of Fura Emeralds Inc. until February 2013. He served as a Director of SG Spirit Gold Inc. (now DOJA Cannabis Company Limited) from March 25, 2014 to September 2014.

CEO Compensation
  • Insufficient data for Mark to compare compensation growth.
  • Insufficient data for Mark to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Brian Gusko

TITLE
AGE
52
TENURE
4.4 yrs

Mark Lotz

TITLE
Interim CEO
AGE
55
TENURE
0.9 yrs

Derek Good

TITLE
Co-Founder & Member of Board of Advisors
Board of Directors Tenure

Average tenure and age of the Vodis Pharmaceuticals board of directors in years:

4.6
Average Tenure
71
Average Age
  • The tenure for the Vodis Pharmaceuticals board of directors is about average.
Board of Directors

Mark Lotz

TITLE
Interim CEO
AGE
55
TENURE
2.2 yrs

Derek Good

TITLE
Co-Founder & Member of Board of Advisors

Otto Folprecht

TITLE
Member of Advisory Committee
COMPENSATION
CA$121K
TENURE
3.8 yrs

Larry Campbell

TITLE
Member of Board of Advisors
AGE
71
TENURE
5.5 yrs

John Reynolds

TITLE
Member of Board of Advisors
AGE
76
TENURE
5.5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Vodis Pharmaceuticals individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
06. Feb 20 Buy Derek Good Individual 04. Feb 20 04. Feb 20 220,000 CA$0.07 CA$14,350
03. Feb 20 Buy Derek Good Individual 03. Feb 20 03. Feb 20 100,000 CA$0.07 CA$7,000
22. Jan 20 Buy Derek Good Individual 21. Jan 20 21. Jan 20 2,000 CA$0.04 CA$80
02. Jan 20 Buy Derek Good Individual 24. Dec 19 27. Dec 19 558,000 CA$0.04 CA$22,213
27. Dec 19 Buy Derek Good Individual 27. Dec 19 27. Dec 19 2,840,453 CA$0.05 CA$142,023
X
Management checks
We assess Vodis Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vodis Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does Market Volatility Impact Vodis Pharmaceuticals Inc.'s (CNSX:VP) Share Price?

Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … Beta is worth considering, but it's also important to consider whether Vodis Pharmaceuticals is growing earnings and revenue. … What this means for you: Since Vodis Pharmaceuticals has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

Do Insiders Own Shares In Vodis Pharmaceuticals Inc. (CNSX:VP)?

As Charlie Munger said 'Show me the incentive and I will show you the outcome.' Vodis Pharmaceuticals is not a large company by global standards. … Check out our latest analysis for Vodis Pharmaceuticals CNSX:VP Ownership Summary, June 26th 2019 What Does The Lack Of Institutional Ownership Tell Us About Vodis Pharmaceuticals? … Insider Ownership Of Vodis Pharmaceuticals The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Vodis Pharmaceuticals Inc. (CNSX:VP) Insiders Have Been Selling

So shareholders might well want to know whether insiders have been buying or selling shares in Vodis Pharmaceuticals Inc. … Check out our latest analysis for Vodis Pharmaceuticals The Last 12 Months Of Insider Transactions At Vodis Pharmaceuticals The , Ivan Miliovski, made the biggest insider sale in the last 12 months. … Vodis Pharmaceuticals insiders didn't buy any shares over the last year.

Simply Wall St -

Investors Who Bought Vodis Pharmaceuticals (CNSX:VP) Shares Three Years Ago Are Now Down 72%

It seems likely some shareholders believe that Vodis Pharmaceuticals will significantly advance the business plan before too long. … Vodis Pharmaceuticals has already given some investors a taste of the bitter losses that high risk investing can cause. … But with the share price diving 34% per year, over 3 years, it's probably fair to say that some shareholders no longer believe the company will succeed.

Simply Wall St -

What Kind Of Shareholder Owns Most Vodis Pharmaceuticals Inc. (CNSX:VP) Stock?

The big shareholder groups in Vodis Pharmaceuticals Inc. … With a market capitalization of CA$6.8m, Vodis Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Vodis Pharmaceuticals

Simply Wall St -

Need To Know: Vodis Pharmaceuticals Inc. (CNSX:VP) Insiders Have Been Selling Shares

We don't think shareholders should simply follow insider transactions. … For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.'? … Vodis Pharmaceuticals Insider Transactions Over The Last Year.

Simply Wall St -

Are Vodis Pharmaceuticals Inc's (CNSX:VP) Interest Costs Too High?

Investors are always looking for growth in small-cap stocks like Vodis Pharmaceuticals Inc (CNSX:VP), with a market cap of CA$7.79m. … However, an important fact which most ignore is: how financially healthy is the business? … Companies operating in the Pharmaceuticals industry,

Simply Wall St -

Company Info

Description

Vodis Pharmaceuticals Inc. operates as an application stage company for producing medical marijuana in Canada and the United States. The company was incorporated in 2011 and is based in Delta, Canada.

Details
Name: Vodis Pharmaceuticals Inc.
VP
Exchange: CNSX
Founded: 2011
CA$3,169,580
79,239,504
Website: http://vodis.ca
Address: Vodis Pharmaceuticals Inc.
8788 River Road,
Delta,
British Columbia, V4G 1B5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX VP Common Shares Canadian National Stock Exchange CA CAD 08. Aug 2014
DB 1JV1 Common Shares Deutsche Boerse AG DE EUR 08. Aug 2014
Number of employees
Current staff
Staff numbers
0
Vodis Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/29 02:30
End of day share price update: 2020/02/28 00:00
Last earnings filing: 2019/11/26
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.